This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genocea Biosciences Valuation

Is GBI1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GBI1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GBI1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GBI1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GBI1?

Key metric: As GBI1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GBI1. This is calculated by dividing GBI1's market cap by their current revenue.
What is GBI1's PS Ratio?
PS Ratio	0.3x
Sales	US$1.91m
Market Cap	US$658.38k

GBI1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GBI1's PS Ratio compare to its peers?

The above table shows the PS ratio for GBI1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.6x
SBH Sangui Biotech International	3.8x	n/a	€419.8k
ECX Epigenomics	1.8x	n/a	€616.0k
PA8 Paion	0.2x	30.2%	€2.6m
CNW co.don	0.7x	n/a	€6.5m
GBI1 Genocea Biosciences	0.3x	-162.1%	€658.4k

Price-To-Sales vs Peers: GBI1 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (5.6x).

Price to Sales Ratio vs Industry

How does GBI1's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	21.8%
GBI1 Genocea Biosciences	0.3x	-162.1%	US$658.38k
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	42.4%
GBI1 Genocea Biosciences	0.3x	-19.8%	US$658.38k

No more companies

Price-To-Sales vs Industry: GBI1 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Biotechs industry average (14.2x)

Price to Sales Ratio vs Fair Ratio

What is GBI1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GBI1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	0.03x

Price-To-Sales vs Fair Ratio: GBI1 is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

1.9%

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

6.7%

3.9%